A Phase 1 interventional study of 99mTc MIP 1404 and 99mTc MIP 1405 in Prostate Cancer, sponsored by Molecular Insight Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to male participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2015-11-25.
Sponsored by Molecular Insight Pharmaceuticals, Inc. · Phase 1, Interventional, and Diagnostic
This is a single-blind, randomized, cross-over design. Patients with metastatic prostate adenocarcinoma; newly diagnosed, high-risk patients with prostate adenocarcinoma; and healthy subjects will be administered a single intravenous dose of each of the study drugs 99mTc MIP 1404 and 99mTc MIP 1405 administered approximately 14 to 21 days apart.
This trial is a single-blind, randomized, cross-over design. Up to six patients with confirmed metastatic prostate adenocarcinoma; six newly diagnosed, high-risk patients with prostate adenocarcinoma; and up to six healthy volunteers will receive 20.0 (± 3) mCi of intravenously administered 99mTc MIP 1404 or 99mTc MIP 1405. Whole-body planar scintigraphic images will be acquired at various times post-injection over 24 hours. A pelvic SPECT/CT image will be acquired on the first day. Blood and urine will be collected for pharmacokinetic measurements and metabolic analysis over 24 hours. Each patient will receive an initial study drug administration and a second study drug administration approximately 14 to 21 days after the first. A final follow-up visit will occur approximately 2-3 weeks after the second study drug.
2,004 studies on the registry are indexed under Adenocarcinoma; 375 are open to participants now.
This study's enrollment of 16 is below the median of 45 across 1,553 interventional studies indexed under Adenocarcinoma.
Browse Adenocarcinoma studies →Molecular Insight Pharmaceuticals, Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants must meet all of the following criteria to be enrolled in this study.
Additional Inclusion Criteria for Patients:
i. Histologic diagnosis of prostate cancer by validated medical history. (Pathology report, if available).
ii. Evidence of metastatic disease demonstrated by a documented abnormal bone scan, CT scan, or MRI plus a Clinical Stage 3 and Gleason Score ≥ 8.
iii. Karnofsky performance is ≥ 60.
Additional Inclusion Criteria for Healthy Volunteers:
i. PSA laboratory assessment within normal range (PSA \< 4 ng/ml). ii. Normal findings on a digital rectal examination. iii. Hemoglobin and hematocrit within normal range.
Exclusion Criteria:
Participants must NOT meet any of the following criteria to be enrolled in this study.
Additional Exclusion Criteria for Patients:
Patients will be excluded from the study if any of the following criteria are observed:
i. Androgen deprivation therapy or other forms of hormonal therapy not stable for a period of 14 days prior to screening.
ii. Subject has received a permanent prostate brachytherapy implant within the last 3 months for 103Pd implants; or 12 months for 125I implants.
iii. Subject on or expected to be starting cytotoxic chemotherapy during the study period.
iv. Has had any other malignancies within the past year, other than basal or squamous cell carcinoma of the skin, diagnosis and location must be defined or be defined as clinically controlled or treated to complete response.
Additional Exclusion Criteria for Healthy Volunteers:
Healthy Volunteers will be excluded from the study if any of the following criteria are observed:
i. Have had any malignancies within 5 years other than basal or squamous cell carcinoma of the skin.
ii. History of known prostate adenocarcinoma, prostate surgery/biopsy, prostatitis and/or symptoms suggestive of or associated with possible prostatitis within 6 months of enrollment.
Radiation: 99mTc MIP 1404 · Radiation: 99mTc MIP 1405
Radiation: 99mTc MIP 1404 · Radiation: 99mTc MIP 1405
Radiation: 99mTc MIP 1404 · Radiation: 99mTc MIP 1405
Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1404
Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1405
Safety of Administered dose
The safety data will be summarized for all patients receiving at least one dose of study drug. Summary tables, including change from pre dose to post dose where applicable, will be presented for the following safety endpoints: * Treatment emergent adverse events * Clinical Laboratory Evaluations * Physical examination, vital signs, and ECGs
Time frame: From the time of signed ICF through 2 weeks post injection of the second study drug administration (up to 8 weeks total for each subject)
Pharmacokinetics of Administered Dose
Standard PK parameters of 99mTc-MIP-1404 and 99mTc-MIP-1405 will be calculated, including but not limited to: clearance, distribution half-life, elimination half-life, mean residence time and maximum concentration. These PK parameters will be listed by subject and summarized. Blood clearance and urinary recovery over time will be displayed in figures. Urine metabolites and impurities of 99mTc-MIP-1404 and 99mTc-MIP-1405 will be listed by subject and summarized. The PK population will be used in the analysis of pharmacokinetics and metabolism.
Time frame: From the time of signed ICF through 2 weeks post injection of the second study drug administration (up to 8 weeks total for each subject)
Biodistribution of Administered Dose
Percent of injected activity (%IA) in a set of source organs will be determined by comparing a reference whole body scan to subsequent whole body scans to determine percentage of administered activity for source organs at the various scanning times. This biodistribution data will then be used to mathematically model source organ residence times, which will be used to estimate radiation absorbed dose to target organs. Percent injected activity and estimated residence times will be summarized by organ.
Time frame: : From the time of signed ICF through 2 weeks post injection of the second study drug administration (up to 8 weeks total for each subject)
Excretion of administered dose
Standard PK parameters of 99mTc-MIP-1404 and 99mTc-MIP-1405 will be calculated, including but not limited to: clearance, distribution half-life, elimination half-life, mean residence time and maximum concentration. These PK parameters will be listed by subject and summarized. Blood clearance and urinary recovery over time will be displayed in figures. Urine metabolites and impurities of 99mTc-MIP-1404 and 99mTc-MIP-1405 will be listed by subject and summarized. The PK population will be used in the analysis of pharmacokinetics and metabolism.
Time frame: From the time of signed ICF through 2 weeks post injection of the second study drug administration (up to 8 weeks total for each subject)
Dosimetry of administered dose
To calculate the estimated radiation dosimetry to normal organs based on the pharmacokinetic and normal tissue distribution in patients with confirmed metastatic prostate adenocarcinoma and in healthy volunteers
Time frame: From the time of signed ICF through 2 weeks post injection of the second study drug administration (up to 8 weeks total for each subject)
Metabolism of administered dose
Standard PK parameters of 99mTc-MIP-1404 and 99mTc-MIP-1405 will be calculated, including but not limited to: clearance, distribution half-life, elimination half-life, mean residence time and maximum concentration. These PK parameters will be listed by subject and summarized. Blood clearance and urinary recovery over time will be displayed in figures. Urine metabolites and impurities of 99mTc-MIP-1404 and 99mTc-MIP-1405 will be listed by subject and summarized. The PK population will be used in the analysis of pharmacokinetics and metabolism.
Time frame: From the time of signed ICF through 2 weeks post injection of the second study drug administration (up to 8 weeks total for each subject)
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Molecular Insight Pharmaceuticals, Inc.